Virtual Presidential Symposium anticipated the “2020 IASLC World Conference on Lung Cancer”
In the sequence of the postponement of the “2020 IASLC World Conference on Lung Cancer” to the beginning of next year, the International Association for the Study of Lung Cancer (IASLC) promoted on August 8th a Virtual Presidential Symposium, which worked as a prelude to the event, anticipating the discussion of some key themes.
In this symposium, some crucial topics for patient care were presented, namely in the context of adjuvant therapy with immunotherapy or targeted therapies in the perioperative period, and of COVID-19 infection in patients with lung cancer.
The results of three studies considered of particular relevance were also revealed:
1) ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC;
2) eXalt3: Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients;
3) CheckMate 743: First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma.
You can watch the full video of the virtual symposium by registering at https://vps2020.iaslc.org/